Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has provided an update.
Shanghai Henlius Biotech, Inc. has announced an extraordinary general meeting to be held on August 29, 2025, to discuss and approve several resolutions. These include the re-appointment and appointment of directors and shareholder representative supervisors, as well as proposed amendments to the Rules of Procedures for the General Meeting, the Board, and the Board of Supervisors. The meeting’s outcomes could impact the company’s governance structure and operational procedures, potentially influencing its strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and production of biologic drugs. The company operates in the pharmaceutical industry, specializing in the creation of biosimilar and innovative biologic products.
Average Trading Volume: 1,333,573
Technical Sentiment Signal: Buy
Current Market Cap: HK$41.79B
For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.